K. Koch

发表

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.

Deborah A. Smith, K. Koch, N. Arya, 2009, British journal of clinical pharmacology.

Effects of food on the relative bioavailability of lapatinib in cancer patients.

A. Stead, R. Cohen, K. Koch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.

J. Lyssikatos, K. Koch, J. Winkler, 2005, Current topics in medicinal chemistry.

Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Anti-inflammatory patent highlights: January-July 1994

K. Koch, L. Burgess, 1995 .

Clinical and Biological Effects of Recombinant Human Interleukin-18 Administered by Intravenous Infusion to Patients with Advanced Cancer

Michael Atkins, William N. Bell, Henry Koon, 2006, Clinical Cancer Research.

A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma

O. Gardner, S. Murray, M. Robertson, 2013, Journal of immunotherapy.

A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer

J. Kirkwood, L. Thurmond, M. Robertson, 2008, Clinical Cancer Research.

Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors

D. Richel, J. Schellens, J. Beijnen, 2007, Clinical Cancer Research.

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

D. Kerr, K. Flaherty, P. O'dwyer, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

S. Mandrekar, T. Gilmer, K. Flatten, 2008, Clinical Cancer Research.

Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice

Deborah H Anderson, K. Koch, J. Winkler, 2012 .

Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity

K. Koch, D. Borts, S. Castellino, 2012, Drug Metabolism and Disposition.

The Role of Efflux and Uptake Transporters in Lapatinib (Tykerb, GW572016) Disposition and Drug Interactions.

Kelly A. Harmon, J. Polli, Lisa St. John-Williams, 2008 .

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

M. Moasser, H. Rugo, A. Goga, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development.

K. Koch, J. Dunn, T. Tobien, 2004, Rapid communications in mass spectrometry : RCM.

Analysis of dermatologic events in patients with cancer treated with lapatinib

H. Gómez, K. Blackwell, M. Lacouture, 2008, Breast Cancer Research and Treatment.

UK‐78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage‐gated potassium channel and inhibits human T cell activation

R. J. Mather, K. Chandy, G. Gutman, 1999, British journal of pharmacology.

A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

David A. Smith, Suzanne F. Jones, A. Stead, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamics and Pharmacokinetics of Oral Contraceptives Co-administered with Alosetron (Lotronex)

K. Kersey, K. Koch, C. Baidoo, 2004, Digestive Diseases and Sciences.

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.

E. Rowinsky, G. Schwartz, J. D. de Bono, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

Sung-Bae Kim, Y. Im, L. Cartee, 2013, Clinical pharmacology in drug development.

Sex and age differences in the pharmacokinetics of alosetron.

K. Koch, J. Palmer, C. Baidoo, 2002, British journal of clinical pharmacology.

Effect of Alosetron on the Pharmacokinetics of Alprazolam

K. Koch, L. Levasseur, D. Robbins, 2001, Journal of clinical pharmacology.

Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine.

I. M. Davis, K. Koch, Y. Yin, 1998, Journal of pharmaceutical sciences.

Effect of lapatinib on oral digoxin absorption in patients

Y. Bang, L. Cartee, J. Botbyl, 2015, Clinical pharmacology in drug development.

Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.

J. Lyssikatos, K. Koch, R. Woessner, 2006, Journal of medicinal chemistry.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Suzanne F. Jones, M. Ellis, A. Stead, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Beta-oxidation of valproic acid. I. Effects of fasting and glucose in humans.

K. Koch, R. Levy, A. Wilensky, 1989, Epilepsia.

Effect of ranitidine on the pharmacokinetics of triazolam and α‐hydroxytriazolam in both young (19‐60 years) and older (61‐78 years) people

D. Williams, K. Kersey, K. Koch, 2001 .

Beta-oxidation of valproate. II. Effects of fasting, glucose, and clofibrate in rats.

T. Baillie, A. Rettenmeier, K. Prickett, 1989, Epilepsia.

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

M. Ellis, A. Stead, K. Blackwell, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver

Dhara N. Amin, Kevan M Shokat, K. Shokat, 2010, Science Translational Medicine.

A phase I dose-escalation study of 5-day intermittent oral lapatinib therapy with biomarker analysis in patients with HER-2-overexpressing breast cancer.

E. Petricoin, M. Moasser, P. Munster, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Vivienne Marsh, S. Gross, B. Brandhuber, 2007, Clinical Cancer Research.

A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

D. Matei, M. Barnes, R. Alvarez, 2008, Gynecologic oncology.

The Role of Efflux and Uptake Transporters in N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) Disposition and Drug Interactions

Kelly A. Harmon, J. Polli, Lisa St. John-Williams, 2008, Drug Metabolism and Disposition.

Evaluation of Lapatinib andTopotecan CombinationTherapy : Tissue Culture , Murine Xenograft , and Phase I ClinicalTrial Data

T. Gilmer, K. Flatten, C. Erlichman, 2008 .

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

J. Golfinos, M. Hagiwara, A. Nusbaum, 2012, Neuro-oncology.

Filtration for free drug level monitoring: carbamazepine and valproic acid.

N. Temkin, K. Koch, V. Raisys, 1984, Therapeutic drug monitoring.

Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients

L. Cartee, R. Swaby, A. D'Amelio, 2015, Clinical pharmacology in drug development.

The value of label recommendations: how to dose lapatinib.

D. Roychowdhury, K. Koch, A. Beelen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

A. Stead, N. Spector, Deborah A. Smith, 2004, Investigational New Drugs.

Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA

J. Thompson, M. Moseley, N. Spector, 2010, Molecular Cancer Therapeutics.

A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).

J. Bogaerts, L. Hayward, P. Fumoleau, 2014, Breast.

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.

J. Bogaerts, J. Bartlett, K. Zaman, 2013, European journal of cancer.

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

Benjamin M Yeh, Lee-may Chen, Yong Huang, 2009, Clinical Cancer Research.

Imaging , Diagnosis , Prognosis A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

N. Hylton, M. Moasser, B. Yeh, 2009 .

Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors.

D. Richel, J. Schellens, J. Beijnen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV)

David A. Smith, D. Kerr, K. Flaherty, 2005 .

Phenytoin–Valproic Acid Interaction in Rhesus Monkey

K. Koch, R. Levy, B. Teri Ludwick, 1981, Epilepsia.

Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study.

A. Stead, D. Smith, H. Hurwitz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.

M. Espié, M. Desilvio, H. Burris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

Suzanne F. Jones, B. Overmoyer, H. Burris, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

E. Rowinsky, L. Goldstein, Q. Chu, 2008, Clinical Cancer Research.

APhase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

E. Rowinsky, L. Goldstein, Q. Chu, 2008 .

Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC)

M. Koehler, H. Burris, J. Crown, 2007 .

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer

H. Lenz, M. Pishvaian, P. Wilson, 2016, Molecular Cancer Therapeutics.

559 Pharmacokinetics of GW572016 in an ascending dose tolerability study of phase I cancer patients

David A. Smith, Suzanne F. Jones, A. Stead, 2003 .

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

J. Schellens, A. Robidoux, L. Cartee, 2014, Investigational New Drugs.

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

Ronald A Fleming, Suzanne F. Jones, Charles W Taylor, 2009, Clinical Cancer Research.

Reply to I.F. Tannock

K. Koch, A. Beelen, N. Reddy, 2009 .

Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate.

I. M. Davis, K. Koch, A. E. Gooding, 1996, British journal of clinical pharmacology.

A phase I dose escalation study of a 2 day lapatinib chemosensitization pulse preceding weekly intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with advanced cancer

N. Hylton, M. Moasser, B. Yeh, 2008 .

Drug Interactions with Valproic Acid

K. Koch, R. Levy, 1982, Drugs.

Effect of Alosetron on the Pharmacokinetics of Fluoxetine

K. Koch, D. Robbins, L. Simms, 2001, Journal of clinical pharmacology.

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.

Patricia M. LoRusso, Ronald A. Fleming, Barbara L. Weber, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors.

M. Mita, E. Rowinsky, L. Hammond, 2004, Journal of Clinical Oncology.

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor

K. Blackwell, L. Cartee, N. Spector, 2015, PloS one.

Effect of Sodium Acid Pyrophosphate on Ranitidine Bioavailability and Gastrointestinal Transit Time

A. Parr, J. Powell, K. Koch, 1993, Pharmaceutical Research.

Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate.

I. M. Davis, K. Koch, A. E. Gooding, 1996, British journal of clinical pharmacology.

Ranitidine pharmacokinetics and central nervous system.

J. Lewis, K. Koch, R. Mcisaac, 1994, Archives of internal medicine.

Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment

I. M. Davis, K. Koch, Y. Yin, 1997, European Journal of Clinical Pharmacology.

Characterization of the metabolites of alosetron in experimental animals and human

D. Saynor, P. Andrew, G. Dear, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

Kelly A. Harmon, J. Polli, Lisa St. John-Williams, 2008, Drug Metabolism and Disposition.

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

S. Gross, J. Lyssikatos, K. Koch, 2010 .

Phase I trial of dasatinib (D) and lapatinib (L).

R. Marks, C. Erlichman, D. Northfelt, 2010 .

A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).

J. Hainsworth, H. Burris, N. Peacock, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.

M. Smith, A. Milici, E. Pettipher, 1998, The Journal of pharmacology and experimental therapeutics.

A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

A. Stead, G. Wilding, H. Burris, 2004, Journal of Clinical Oncology.

Preclinical development of ARRY-142886, a potent and selective MEK inhibitor

S. Gross, B. Brandhuber, T. Morales, 2004 .

PK and PD of recombinant human IL-18 (rhIL-18) administered IV in repeated cycles to patients with solid tumors

J. Kirkwood, M. Robertson, K. Koch, 2005 .

Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA

J. Thompson, N. Spector, S. Bacus, 2010, Molecular Cancer Therapeutics.

Effect of alosetron on theophylline pharmacokinetics.

K. Kersey, K. Koch, D. Jewell, 2001, British Journal of Clinical Pharmacology.

Role of pharmacogenetic studies in early clinical development: Phase I studies with lapatinib.

M. Ehm, A. Stead, L. Briley, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

J. Golfinos, M. Hagiwara, A. Nusbaum, 2012, Neuro-oncology.